Sarepta Therapeutics Inc (NASDAQ:SRPT)’s traded shares stood at 0.49 million during the latest session, with the company’s beta value hitting 0.92. At the last check today, the stock’s price was $49.67, to imply a decrease of -1.27% or -$0.64 in intraday trading. The SRPT share’s 52-week high remains $173.25, putting it -248.8% down since that peak but still an impressive 3.34% since price per share fell to its 52-week low of $48.01. The company has a valuation of $4.82B, with an average of 3.62 million shares in intraday trading volume over the past 10 days and average of 1.76 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Sarepta Therapeutics Inc (SRPT), translating to a mean rating of 1.40. Of 17 analyst(s) looking at the stock, 1 analyst(s) give SRPT a Sell rating. 0 of those analysts rate the stock as Overweight while 6 advise Hold as 10 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.08.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
After registering a -1.27% downside in the latest session, Sarepta Therapeutics Inc (SRPT) has traded red over the past five days. The 5-day price performance for the stock is -8.75%, and -49.51% over 30 days. With these gigs, the year-to-date price performance is -59.15%. Short interest in Sarepta Therapeutics Inc (NASDAQ:SRPT) saw shorts transact 4.85 million shares and set a 4.51 days time to cover.
The extremes give us $165 and $202 for target low and target high price respectively. As such, SRPT has been trading -306.68% off suggested target high and -232.19% from its likely low.
Sarepta Therapeutics Inc (SRPT) estimates and forecasts
The rating firms project that company’s revenue will grow 61.04% compared to the previous financial year.
Revenue forecast for the current quarter as set by 16 analysts is 677.06M. Meanwhile, for the current quarter, a total of 17 analyst(s) estimate revenue growth to 745.28M.Earnings reports from the last fiscal year show that sales brought in 413.46M and 362.93M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 63.75% before jumping 105.35% in the following quarter.
SRPT Dividends
Sarepta Therapeutics Inc has its next earnings report out on 2025-Feb-25. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders
Sarepta Therapeutics Inc insiders hold 4.41% of total outstanding shares, with institutional holders owning 92.27% of the shares at 96.53% float percentage. In total, 92.27% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 10.32 million shares (or 10.9117% of shares), all amounting to roughly $1.63 billion.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 9.04 million shares, or about 9.6133% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.43 billion.
We also have GROWTH FUND OF AMERICA and iShares Trust-iShares Core S&P Mid-Cap ETF as the top two Mutual Funds with the largest holdings of the Sarepta Therapeutics Inc (SRPT) shares. Going by data provided on Dec 31, 2024 , GROWTH FUND OF AMERICA holds roughly 3.16 shares. This is just over 3.25% of the total shares, with a market valuation of $157.18 million. Data from the same date shows that the other fund manager holds a little less at 3.12, or 3.22% of the shares, all valued at about 155.42 million.
